 
 Jules Mitchel  of Target Health discusses What is different now about risk-based monitoring vs. what companies may have been doing more innovatively about monitoring in the past in the clinical trials industry.

Risk-Based Monitoring – Part Two In Depth Review

Increasing Intensity of On-Site Monitoring a Troubling Trend

Industry Metric Indicates Low ROI with Full Source Document Verification

Has FDA Guidance on Risk-based Monitoring Impacted SDV Coverage Yet?

News

Jules Mitchel of Target Health discusses risk-based monitoring trends in the clinical trials industry